{"aaData": [["100409", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "", "
\nThis term represents the fraction of T-cells that are LRBA positive.\n\n
\nThis term represents the LRBA fluorescent intensity among T-cells (CD3+)\n\n
\nThis term represents the fraction of B-cells that are LRBA positive.\n\n
\nThis term represents the fluorescent intensity of LRBA among B-cells.\n\n
\nGlial fibrillary acidic protein concentration levels differ from a system of ser\num and plasma. The plasma values are higher than serum for GFAP as confirmation.\n\n
\nUbiquitin carboxyl-terminal hydrolase-L1 protein concentration levels differ fro\nm a system of serum and plasma.\n\n
\nIdentification of RHD gene (indicating Rhesus D positive fetus) in fetal DNA ext\nracted from maternal blood sample.\n\n
\nThis test is to identify disease causing variants in genes associated with chron\nic kidney disease.\n\n
\nThe GAAD score is used to predict the probability of developing early-stage hepa\ntocellular carcinoma (HCC). It is calculated based on gender, age, alpha-fetopro\ntein (AFP), and des-gamma-carboxy prothrombin (DCP, also called PIVKA-II). In co\nntrast, the GALAD score [LOINC: 96450-2] includes AFP-L3. The risk-factor score \nranges from 0-10 where a higher GAAD scores correlate with increased risk of HCC\n.\n\n
\nThis LOINC code can be used for analysis of genes including but not limited to t\nhe following: ANO6, AP3B1, BLOC1S3, BLOC1S6,DTNBP1, FGA, FGB, FGG, GP1BA, GP1BB,\n GP6, GP9, HPS1, HPS3, HPS4, HPS5, HPS6, ITGA2B, ITGB3, LYST, MYH9, P2RY12, PLA2\nG7, PLAU, RASGRP2, TBXA2R, TBXAS1, VIPAS39, VPS33B, VWF, WAS. Disease diagnosed\n can include Glanzmann's Thrombasthenia, Bernard-Soulier Syndrome, and others.\n\n
\nScreening for Mycobacterium bovis consists of an intradermal dose of tuberculin \nnormally read and reported qualitatively as reaction present or absent. If a res\nponse is noted, a comparative test to distinguish between M bovis and M avium is\n performed by a regulatory veterinarian.\n\n
\n? 2019 National POLST. The National POLST Form may only be used for non-commerci\nal, personal purposes. Commercial or facility use requires a license from Nation\nal POLST or an authorized reseller. For use options or to discuss permissions, p\nlease visit: https://polst.org/terms/.\n\n
\nCodes for the National POLST Form: A Portable Medical Order and other portable m\nedical order forms [https://polst.org].\n\n
\n? 2019 National POLST. The National POLST Form may only be used for non-commerci\nal, personal purposes. Commercial or facility use requires a license from Nation\nal POLST or an authorized reseller. For use options or to discuss permissions, p\nlease visit: https://polst.org/terms/.\n\n
\nThe Cardiopulmonary Resuscitation Orders item in the National POLST Portable Med\nical Orders form, which specifies the action to take if the patient has no pulse\n and is not breathing [https://polst.org/].\n\n
\n? 2019 National POLST. The National POLST Form may only be used for non-commerci\nal, personal purposes. Commercial or facility use requires a license from Nation\nal POLST or an authorized reseller. For use options or to discuss permissions, p\nlease visit: https://polst.org/terms/.\n\n
\nThe Initial Treatment Orders item in the National POLST Portable Medical Orders \nform, which specifies the action to take if the patient has a pulse and/or is br\neathing [https://polst.org].\n\n
\n? 2019 National POLST. The National POLST Form may only be used for non-commerci\nal, personal purposes. Commercial or facility use requires a license from Nation\nal POLST or an authorized reseller. For use options or to discuss permissions, p\nlease visit: https://polst.org/terms/.\n\n
\nThe Additional Orders or Instructions item in the National POLST Portable Medica\nl Orders form, which provides the option to issue orders not defined in other po\nrtions of the National ePOLST Form: A Portable Medical Order (e.g., blood produc\nts, dialysis) [https://polst.org].\n\n
\n? 2019 National POLST. The National POLST Form may only be used for non-commerci\nal, personal purposes. Commercial or facility use requires a license from Nation\nal POLST or an authorized reseller. For use options or to discuss permissions, p\nlease visit: https://polst.org/terms/.\n\n
\nThe Medically Assisted Nutrition item in the National POLST Portable Medical Ord\ners form [https://polst.org].\n\n
\n? 2019 National POLST. The National POLST Form may only be used for non-commerci\nal, personal purposes. Commercial or facility use requires a license from Nation\nal POLST or an authorized reseller. For use options or to discuss permissions, p\nlease visit: https://polst.org/terms/.\n\n
\nInformation on a review of the portable medical order form and an advance direct\nive, if such exists for the patient [https://polst.org].\n\n
\n? 2019 National POLST. The National POLST Form may only be used for non-commerci\nal, personal purposes. Commercial or facility use requires a license from Nation\nal POLST or an authorized reseller. For use options or to discuss permissions, p\nlease visit: https://polst.org/terms/.\n\n
\nInformation on all who participated in the portable medical order form completio\nn and review [https://polst.org].\n\n
\n? 2019 National POLST. The National POLST Form may only be used for non-commerci\nal, personal purposes. Commercial or facility use requires a license from Nation\nal POLST or an authorized reseller. For use options or to discuss permissions, p\nlease visit: https://polst.org/terms/.\n\n
\nAdministrative, instructional, and/or legal information that must be present on \nan exchange of an ePOLST document [https://polst.org].\n\n
\nFast is a score used by healthcare professionals to aid in the identification o\nf patients with suspicion of NAFLD as being at risk for active fibrotic NASH (NA\nSH+NAS?4+F?2). Fast is computed from liver stiffness by US.transient elastograph\ny, liver ultrasound attenuation by transient elastography, and AST blood paramet\ner measurement. More information and the formula can be found at https://www.ech\nosens.com/products/fast.\n\n
\nAgile is a set of scores estimating the degree of liver fibrosis in patients wit\nh suspicion of nonalcoholic liver diseases. Agile 3+ is based on Liver Stiffness\n measurement and a variety of parameters (e.g. lab parameters AST, ALT, Platelet\ns and Age, Gender, Diabetes status) to assess the probably of advanced fibrosis.\n More information and the formula can be found at https://www.echosens.com/produ\ncts/agile-3/.\n\n
\nAgile is a set of scores estimating the degree of liver fibrosis in patients wit\nh suspicion of nonalcoholic liver diseases. Agile 4 is based on Liver Stiffness \nmeasurement and a variety of parameters (e.g. lab parameters AST, ALT, Platelets\n and Gender, Diabetes status) to assess the probably of cirrhosis. More informat\nion and the formula can be found at https://www.echosens.com/products/agile-4/.\n\n
\nCopyright ? 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Ti\nm Benson by email: tim.benson@r-outcomes.com Used with permission\n\n
\nEach level is indicated using a traffic-light metaphor with written labels, colo\nr, position and emojis. For individuals, each item response level is scored on a\n 0-3 ordinal scale, with strongly agree = 3, agree = 2, neutral = 1, and disagre\ne = 0. A summary score is calculated by adding the item scores for each item and\n giving a scale from 0 to 12. A summary score is not calculated if any item scor\nes are missing. For cohorts, mean scores are shown on a 0 to 100 scale. Item sco\nres are multiplied by 100 and divided by 3; summary scores are multiplied by 100\n and divided by 12. Mean scores are usually rounded to the nearest whole number \n[PMID: 32198234].\n\n
\nCopyright ? 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Ti\nm Benson by email: tim.benson@r-outcomes.com Used with permission\n\n
\nThe user satisfaction panel captures patients' perception of innovation usabilit\nusually rounded to the nearest whole number [PMID: 32198234].\ny, effectiveness, and overall satisfaction. Each level is indicated using a traf\nfic-light metaphor with written labels, color, position and emojis. For individu\nals, each item response level is scored on a 0-3 ordinal scale, with strongly ag\nree = 3, agree = 2, neutral = 1, and disagree = 0. A summary score is calculated\n by adding the item scores for each item and giving a scale from 0 to 12. A summ\nary score is not calculated if any item scores are missing. For cohorts, mean sc\nores are shown on a 0 to 100 scale. Item scores are multiplied by 100 and divide\nd by 3; summary scores are multiplied by 100 and divided by 12. Mean scores are \n\n
\nCopyright ? 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Ti\nm Benson by email: tim.benson@r-outcomes.com Used with permission\n\n
\nThe privacy panel captures patients' perception of data protection, data sharing\nd to the nearest whole number [PMID: 32198234].\n, and information governance. Each level is indicated using a traffic-light meta\nphor with written labels, color, position and emojis. For individuals, each item\n response level is scored on a 0-3 ordinal scale, with strongly agree = 3, agree\n = 2, neutral = 1, and disagree = 0. A summary score is calculated by adding the\n item scores for each item and giving a scale from 0 to 12. A summary score is n\not calculated if any item scores are missing. For cohorts, mean scores are shown\n on a 0 to 100 scale. Item scores are multiplied by 100 and divided by 3; summar\ny scores are multiplied by 100 and divided by 12. Mean scores are usually rounde\n\n
\nCopyright ? 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Ti\nm Benson by email: tim.benson@r-outcomes.com Used with permission\n\n
\nEach level is indicated using a traffic-light metaphor with written labels, colo\nr, position and emojis. For individuals, each item response level is scored on a\n 0-3 ordinal scale, with strongly agree = 3, agree = 2, neutral = 1, and disagre\ne = 0. A summary score is calculated by adding the item scores for each item and\n giving a scale from 0 to 12. A summary score is not calculated if any item scor\nes are missing. For cohorts, mean scores are shown on a 0 to 100 scale. Item sco\nres are multiplied by 100 and divided by 3; summary scores are multiplied by 100\n and divided by 12. Mean scores are usually rounded to the nearest whole number \n[PMID: 32198234].\n\n
\nCopyright ? 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Ti\nm Benson by email: tim.benson@r-outcomes.com Used with permission\n\n
\nThe digital confidence panel identifies patients' confidence using digital devic\nly rounded to the nearest whole number [PMID: 32198234].\nes, applications, and similar devices. Each level is indicated using a traffic-l\night metaphor with written labels, color, position and emojis. For individuals, \neach item response level is scored on a 0-3 ordinal scale, with strongly agree =\n 3, agree = 2, neutral = 1, and disagree = 0. A summary score is calculated by a\ndding the item scores for each item and giving a scale from 0 to 12. A summary s\ncore is not calculated if any item scores are missing. For cohorts, mean scores \nare shown on a 0 to 100 scale. Item scores are multiplied by 100 and divided by \n3; summary scores are multiplied by 100 and divided by 12. Mean scores are usual\n\n
\nCopyright ? 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Ti\nm Benson by email: tim.benson@r-outcomes.com Used with permission\n\n
\nEach level is indicated using a traffic-light metaphor with written labels, colo\nr, position and emojis. For individuals, each item response level is scored on a\n 0-3 ordinal scale, with strongly agree = 3, agree = 2, neutral = 1, and disagre\ne = 0. A summary score is calculated by adding the item scores for each item and\n giving a scale from 0 to 12. A summary score is not calculated if any item scor\nes are missing. For cohorts, mean scores are shown on a 0 to 100 scale. Item sco\nres are multiplied by 100 and divided by 3; summary scores are multiplied by 100\n and divided by 12. Mean scores are usually rounded to the nearest whole number \n[PMID: 32198234].\n\n
\nCopyright ? 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Ti\nm Benson by email: tim.benson@r-outcomes.com Used with permission\n\n
\nThe personal safety panel captures patients' perceptions about personal safety, \n. Mean scores are usually rounded to the nearest whole number [PMID: 32198234].\nphysical safety, and emotional safety in or outside the home. Each level is indi\ncated using a traffic-light metaphor with written labels, color, position and em\nojis. For individuals, each item response level is scored on a 0-3 ordinal scale\n, with strongly agree = 3, agree = 2, neutral = 1, and disagree = 0. A summary s\ncore is calculated by adding the item scores for each item and giving a scale fr\nom 0 to 12. A summary score is not calculated if any item scores are missing. Fo\nr cohorts, mean scores are shown on a 0 to 100 scale. Item scores are multiplied\n by 100 and divided by 3; summary scores are multiplied by 100 and divided by 12\n\n
\nCopyright ? 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Ti\nm Benson by email: tim.benson@r-outcomes.com Used with permission\n\n
\nEach level is indicated using a traffic-light metaphor with written labels, colo\nr, position and emojis. For individuals, each item response level is scored on a\n 0-3 ordinal scale, with strongly agree = 3, agree = 2, neutral = 1, and disagre\ne = 0. A summary score is calculated by adding the item scores for each item and\n giving a scale from 0 to 12. A summary score is not calculated if any item scor\nes are missing. For cohorts, mean scores are shown on a 0 to 100 scale. Item sco\nres are multiplied by 100 and divided by 3; summary scores are multiplied by 100\n and divided by 12. Mean scores are usually rounded to the nearest whole number \n[PMID: 32198234].\n\n
\nCopyright ? 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Ti\nm Benson by email: tim.benson@r-outcomes.com Used with permission\n\n
\nThe neighbor relationships panel identifies patients' neighbor relationships, co\ny rounded to the nearest whole number [PMID: 32198234].\nmmunity cohesion, and social capital. Each level is indicated using a traffic-li\nght metaphor with written labels, color, position and emojis. For individuals, e\nach item response level is scored on a 0-3 ordinal scale, with strongly agree = \n3, agree = 2, neutral = 1, and disagree = 0. A summary score is calculated by ad\nding the item scores for each item and giving a scale from 0 to 12. A summary sc\nore is not calculated if any item scores are missing. For cohorts, mean scores a\nre shown on a 0 to 100 scale. Item scores are multiplied by 100 and divided by 3\n; summary scores are multiplied by 100 and divided by 12. Mean scores are usuall\n\n
\nCopyright ? 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Ti\nm Benson by email: tim.benson@r-outcomes.com Used with permission\n\n
\nEach level is indicated using a traffic-light metaphor with written labels, colo\nr, position and emojis. For individuals, each item response level is scored on a\n 0-3 ordinal scale, with strongly agree = 3, agree = 2, neutral = 1, and disagre\ne = 0. A summary score is calculated by adding the item scores for each item and\n giving a scale from 0 to 12. A summary score is not calculated if any item scor\nes are missing. For cohorts, mean scores are shown on a 0 to 100 scale. Item sco\nres are multiplied by 100 and divided by 3; summary scores are multiplied by 100\n and divided by 12. Mean scores are usually rounded to the nearest whole number \n[PMID: 32198234].\n\n
\nCopyright ? 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Ti\nm Benson by email: tim.benson@r-outcomes.com Used with permission\n\n
\nEach level is indicated using a traffic-light metaphor with written labels, colo\nr, position and emojis. For individuals, each item response level is scored on a\n 0-3 ordinal scale, with hardly ever = 3, occasionally = 2, sometimes = 1, and o\nften = 0. A summary score is calculated by adding the item scores for each item \nand giving a scale from 0 to 12. A summary score is not calculated if any item s\ncores are missing. For cohorts, mean scores are shown on a 0 to 100 scale. Item \nscores are multiplied by 100 and divided by 3; summary scores are multiplied by \n100 and divided by 12. Mean scores are usually rounded to the nearest whole numb\ner [PMID: 32198234].\n\n
\nCopyright ? 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Ti\nm Benson by email: tim.benson@r-outcomes.com Used with permission\n\n
\nThe loneliness (ONS) panel is an alternative to other loneliness panel based on \ns are multiplied by 100 and divided by 3; summary scores are multiplied by 100 a\nnd divided by 12. Mean scores are usually rounded to the nearest whole number [P\nMID: 32198234].\nthe United Kingdom's Office of National Statistics (ONS). The loneliness (ONS) p\nanel captures patients' perception of loneliness and social relationships. Each \nlevel is indicated using a traffic-light metaphor with written labels, color, po\nsition and emojis. For individuals, each item response level is scored on a 0-3 \nordinal scale, with hardly ever = 3, occasionally = 2, sometimes = 1, and often \n= 0. A summary score is calculated by adding the item scores for each item and g\niving a scale from 0 to 12. A summary score is not calculated if any item scores\n are missing. For cohorts, mean scores are shown on a 0 to 100 scale. Item score\n\n
\nCopyright ? 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Ti\nm Benson by email: tim.benson@r-outcomes.com Used with permission\n\n
\nThe product confidence panel identifies patients' confidence and understanding u\nes are usually rounded to the nearest whole number [PMID: 32198234].\nsing specific innovation, application, or product. Each level is indicated using\n a traffic-light metaphor with written labels, color, position and emojis. For i\nndividuals, each item response level is scored on a 0-3 ordinal scale, with stro\nngly agree = 3, agree = 2, neutral = 1, and disagree = 0. A summary score is cal\nculated by adding the item scores for each item and giving a scale from 0 to 12.\n A summary score is not calculated if any item scores are missing. For cohorts, \nmean scores are shown on a 0 to 100 scale. Item scores are multiplied by 100 and\n divided by 3; summary scores are multiplied by 100 and divided by 12. Mean scor\n\n
\nCopyright ? 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Ti\nm Benson by email: tim.benson@r-outcomes.com Used with permission\n\n
\nEach level is indicated using a traffic-light metaphor with written labels, colo\nr, position and emojis. For individuals, each item response level is scored on a\n 0-3 ordinal scale, with strongly agree = 3, agree = 2, neutral = 1, and disagre\ne = 0. A summary score is calculated by adding the item scores for each item and\n giving a scale from 0 to 12. A summary score is not calculated if any item scor\nes are missing. For cohorts, mean scores are shown on a 0 to 100 scale. Item sco\nres are multiplied by 100 and divided by 3; summary scores are multiplied by 100\n and divided by 12. Mean scores are usually rounded to the nearest whole number \n[PMID: 32198234].\n\n
\nCopyright ? 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Ti\nm Benson by email: tim.benson@r-outcomes.com Used with permission\n\n
\nThe digital readiness panel identifies patients' readiness to use digital innova\nded to the nearest whole number [PMID: 32198234].\ntions and their innovativeness. Each level is indicated using a traffic-light me\ntaphor with written labels, color, position and emojis. For individuals, each it\nem response level is scored on a 0-3 ordinal scale, with strongly agree = 3, agr\nee = 2, neutral = 1, and disagree = 0. A summary score is calculated by adding t\nhe item scores for each item and giving a scale from 0 to 12. A summary score is\n not calculated if any item scores are missing. For cohorts, mean scores are sho\nwn on a 0 to 100 scale. Item scores are multiplied by 100 and divided by 3; summ\nary scores are multiplied by 100 and divided by 12. Mean scores are usually roun\n\n
\nCopyright ? 2008-2021 R-Outcomes Ltd. All rights reserved.Users should notify Ti\nm Benson by email: tim.benson@r-outcomes.com Used with permission\n\n
\nEach level is indicated using a traffic-light metaphor with written labels, colo\nr, position and emojis. For individuals, each item response level is scored on a\n 0-3 ordinal scale, with strongly agree = 3, agree = 2, neutral = 1, and disagre\ne = 0. A summary score is calculated by adding the item scores for each item and\n giving a scale from 0 to 12. A summary score is not calculated if any item scor\nes are missing. For cohorts, mean scores are shown on a 0 to 100 scale. Item sco\nres are multiplied by 100 and divided by 3; summary scores are multiplied by 100\n and divided by 12. Mean scores are usually rounded to the nearest whole number \n[PMID: 32198234].\n\n
\n? 2019 National POLST. The National POLST Form may only be used for non-commerci\nal, personal purposes. Commercial or facility use requires a license from Nation\nal POLST or an authorized reseller. For use options or to discuss permissions, p\nlease visit: https://polst.org/terms/.\n\n
\nThe completion information portion of the standardized electronic representation\n of the National POLST Portable Medical Orders form [https://polst.org].\n\n
\nDuring pregnancy, a two-step immunoassay procedure which involves an extra step \nto remove interfering substances can be performed. There are often separate re\nference intervals by gestational age.\n\n
\nThe Respiratory Allergen Mix Area 5 looks for allergens that are commonly found \nin Indiana, Kentucky, Ohio, Tennessee, West Virginia.\n\n
\nThis term honors the lasting legacy of Dr. Daniel J. Vreeman as a perennial advo\ncate of health data standards. Dr. Vreeman led the international growth and adop\ntion of LOINC during his tenure as director. Dan's commitment to building a seam\nless network of health information systems is unparalleled.\n\n
\nThis term honors the countless contributions of John L. Hook to create and conti\nnually improve the technical infrastructure of LOINC during his 24-year career a\nt Regenstrief Institute. John is a thought leader to any and all who use LOINC t\nhroughout the world. John's earnestness and kindness toward all helped make him\n the heart of LOINC.\n\n
\nThe National Council of State Boards of Nursing (NCSBN) ID is a unique, eight-di\ngit number assigned to every nurse upon their first licensure with the board of \nnursing. It's the only unique nurse identifier for all nurses and allows concise\n communication among systems while still protecting a nurse's personal informati\non. NCSBN ID numbers are available through the NURSYS system. [https://www.ncsbn\n.org/nursys.htm]\n\n
\nThe theoretical limit of detection for the patient sample, which at one referenc\ne laboratory, is calculated as 20 abnormal PC events divided by the actual numbe\nr of non-aggregate events collected from the sample.\n\n
\nB-cell precursors are cells that differentiate into mature B lymphocytes. The fo\nur major types of B-cell precursors are pro-B-cells, pre-B-I cells, pre-B-II cel\nls, and immature cells. [PMID: 31849931]\n\n
\nA notice or communications to notify clinicians and patients about appointments \nlike preventive screenings or vaccinations. [PMID: 26749357]\n\n
\nUseful for: evaluation of loss of response to therapy; quantification of ustekin\numab in human serum; trough level quantitation for evaluation of patients treate\nd with ustekinumab; and detection of antibodies to ustekinumab in human serum.\n\n
\nFlow cytometric immunophenotyping of peripheral blood is performed to evaluate t\nhe percentage of classical monocytes (MO1)\n\n
\nThe mean banding resolution (i.e., number of bands) obtained for chromosome anal\nysis.\n\n
\nSpeciociliatine is a diastereomer of mitragynine and is an indole-based alkaloi\nd found in kratom (Mitragyna speciosa) [PMID: 35854066].\n\n
\nThis is an observation to indicate the relevant jurisdiction that accepts an adv\nance directive document. The answers to the question "What jurisdiction accepts\n this document?" are provided in the following value set. http://hl7.org/fhir/R4\n/valueset-jurisdiction.html\n\n
\nThis panel contains IgG antibody tests for ehrlichiosis and babesiosis bacterial\n diseases transmitted by tick bites and caused by three infecting species: Ehrli\nchia chaffeensis and Anaplasma phagocytophilum and Babesia microti.\n\n
\nThe level of similarity score indicates how similar the result from an unknown s\nample is to a reference sample. A higher score indicates that identification is \npossible at the species level, versus an intermediate score that allows identifi\ncation at the genus level. Low scores do not allow identification of the organis\nm from the unknown sample. The specific scores at which genus- and species-level\n identification is possible vary by microorganism. [PMID: 28143403]\n\n
\nCopyright ? 2006 Razmus & Wilson. Used with permission.\n\n
\nCopyright ? 2006 Razmus & Wilson. Used with permission.\n\n
\nA score of 1 or greater is considered high risk for falls.\n\n
\nCopyright ? 2006 Razmus & Wilson. Used with permission.\n\n
\nScores for the first 4 items (CHAM) are summed. Total score range is 0 to 4.\n\n
\nA risk adjustment coding gap report contains information about Condition Categor\ny or HCC coding gaps for a patient.\n\n
\nThis is a veterinary test and can includes specimen types as determined by the d\niagnostician.\n\n
\nThis is a veterinary test and can include a variety of specimen types such as e\nnvironmental, swabs, stool, oral fluids, tissues, isolates and others as determi\nned by the diagnostician.\n\n
\nIncludes a variety of specimen types such as environmental, swabs, stool, oral f\nluids, tissues, isolates and others as determined by the diagnostician.\n\n
\nIncludes a variety of specimen types such as cultures, swabs, washes, oral flui\nds, isolates and others as determined by the diagnostician.\n\n
\nThis mutation is a single nucleotide adenine to guanine substitution at nucleoti\nde 2,254, corresponding to an asparagine to aspartic acid substitution. Includes\n a variety of specimen types such as organs, tissues, and isolates and others a\ns determined by the diagnostician.\n\n
\nThis mutation is a single nucleotide adenine to guanine substitution located at \nnucleotide 2254, corresponding to an asparagine to aspartic acid substitution. \n Includes a variety of specimen types such as organs, tissues, isolates and oth\ners as determined by the diagnostician.\n\n
\nInclude a variety of specimen types such as serum, plasma, milk or colostrum, a\nnd others as determined by the diagnostician.\n\n
\nIncludes a variety of specimen types such as cultures, swabs, stool, organs, ti\nssues, isolates and others as determined by the diagnostician.\n\n
\nIncludes a variety of specimen types such as cultures, tendons, tissues, isolat\nes and others as determined by the diagnostician.\n\n
\nIncludes a variety of specimen types such as lavages, swabs, stool, tissues, an\nd others as determined by the diagnostician.\n\n
\nIncludes a variety of specimen types such as serum, plasma, colostrum, and othe\nrs as determined by the diagnostician.\n\n
\nPercent genomic homology between a new isolated PRRS virus strain and a PPRS vac\ncine strain is based on the number of matching amino acids per total amino acids\n sequenced in the open reading frame 5 (ORF5) gene. The more homologous the ORF5\n gene sequences, the more closely the variants are related.\n\n
\nInclude a variety of specimen types such as cultures, fixed skin biopsies, isol\nates, and others as determined by the diagnostician.\n\n
\nInclude a variety of specimen types such as cultures, fixed skin biopsies, isol\nates, and others as determined by the diagnostician.\n\n
\nThis test is based on sequencing and targeted analysis of specific variants . T\nhe testing depends largely upon the individual's ethnic background. A negative r\nesult may indicate a reduced carrier risk for some or all diseases being tested,\n this risk cannot be eliminated.\n\n
\nThis panel contains markers that help determine whether a patient has a bacteria\nl or viral infection in patients presenting with signs of infection.\n\n
\nThe test generates a numeric score that falls within discrete interpretation cat\negories based on the increasing likelihood of bacterial infection based on mach\nine learning algorithm and computational models.\n\n
\nThis code is used for assays that detect the presence of phenylalanine at amino\n acid position 158 in the CD16 protein product of the FCGR3A gene.\n\n
\nThis code is used for assays that detect the presence of valine at amino acid po\nsition 158 in the CD16 protein product of the FCGR3A gene.\n\n
\nHepatocyte Paraffin 1 is a monoclonal antibody that has been developed to react \nto hepatocytes in surgical pathology specimens. The antibody stains hepatocellul\nar carcinomas.\n\n
\nCopyright ? 1990 Used with permission.\n\n
\nTotal score calculated ranging from 0 to 6.\n\n
\nCopyright ? 1990 Used with permission.\n\n
\nTotal score values of 3 or above indicate patient at risk for falls and total sc\nore values of less than 3 indicate lower risk of falls.\n\n
\nThe patient's allelic genotype for the VKORC1 gene allele. Testing may include t\nhe most common alleles of VKORC1 , such as 1*,2*,3*,4*. The example answers prov\nided with this code are a small representative of the VKORC1 allelic genotypes.\n\n
\nPercentage or longer explanatory comment\n\n
\nThis term is intended to report on genetic abnormalities in genes that can help \nin the diagnosis and prognosis of B-cell lymphomas.\n\n
\nPanel test for the measurement of glucose and growth hormone (post glucose admin\nistration) in timed increments.\n\n
\nEvaluation of potential neonate recipients of blood or blood products as an aid \nto selection of compatible products.\n\n
\nDetection of pathologic prions in cerebrospinal fluid (CSF). The test uses recom\nbinant prion protein (PrP) as a reagent substrate and patient CSF in a real-time\n quaking-induced conversion (RT-QuIC) assay. If pathologic prions are present in\n the patient's CSF, they propagate misfolding of the reagent PrP to form amyloid\n, which is detected using a fluorescent indicator. RT-QuIC has been adopted in c\nlinical practice due to the sensitivity, specificity, and use of CSF (not a brai\nn biopsy) for testing. The reported sensitivity of RT-QuIC in detecting CJD is >\n90%, and the specificity approaches 100%.\n\n
\nDetecting of adult, pediatric and specific neoplastic clones associated with th\ne common chromosome abnormalities and classic rearrangements observed in patient\ns with T-cell acute lymphoblastic leukemia (T-ALL) using client specified probes\n\n
\nThis term can be used to encode testing for the following four kinase-activating\n chromosome rearrangements, as well as for IKZF1 deletion, which often accompani\nes Ph-like ALL, plus other gene rearrangements and translocations: 1q25 rearran\ngement, ABL2 5q32 rearrangement, PDGFRB 9p24.1 rearrangement, JAK2 9q34 rearr\nangement, ABL1 7p-, IKZF1/CEP7 t(Xp22.33;var) or t(Yp11.32;var), CRLF2 rearran\ngement t(Xp22.33;var) or t(Yp11.32;var), P2RY8 rearrangement\n\n
\nThis panel contains results for electrophoresis testing as well as monoclonal pr\notein isotype by MALDI-TOF, and is used for diagnosing monoclonal gammopathies u\nsing 24 Hour urine specimens.\n\n
\nIdentifying monoclonal gammopathy isotypes using 24H urine specimens.\n\n
\nIdentifying monoclonal gammopathies using 24H urine specimens.\n\n
\nThis panel contains results for electrophoresis testing as well as monoclonal pr\notein isotype by MALDI-TOF, and is used for diagnosing monoclonal gammopathies u\nsing random urine specimens.\n\n
\nIdentifying monoclonal gammopathy isotypes using random urine specimens.\n\n
\nIdentifying monoclonal gammopathies using random urine specimens.\n\n
\nEvaluation of isolated and syndromic causes and management of Wilms tumor.\n\n
\nDetection of allo- or autoantibodies directed against red blood cell antigens in\n the settings of pretransfusion testing\n\n
\nEvaluation of potential recipients of blood or blood products as an aid to selec\ntion of compatible products.\n\n
\nEvaluation of potential neonate recipients of blood or blood products as an aid \nto selection of compatible products\n\n
\nRequesting an Order code.We have all the result components added below.\n\n
\nThe PCL-5 is a 20-item self-report measure of the DSM-5 symptoms of PTSD. The wo\nt has experienced at least one Criterion A event.\nrding of PCL-5 items reflects both changes to existing symptoms and the addition\n of new symptoms in DSM-5. The PCL has a variety of purposes including, screen\ning individuals for PTSD, diagnosing PTSD and monitoring symptom change during a\nnd after treatment. The PCL-C (civilian) asks about symptoms in relation to "str\nessful experiences." The PCL-C is useful because it can be used with any populat\nion. The symptoms endorsed may not be specific to just one event, which can be h\nelpful when assessing survivors who have symptoms due to multiple events. Typica\nlly, it is optimal to assess traumatic event exposure to ensure that a responden\n\n
\nNickel allergy is the most prevalent contact allergy. It belongs to a different \nhypersensitivity type to asthma and rhinoconjunctivitis. Self-reported nickel al\nlergy is associated with incident wheezing. [PMID: 32039258]\n\n
\nQualitative and Quantitative assay for SARS-CoV-2 RNA using PCR method\n\n
\nCalcium hydrogen phosphate dihydrate (CHPD) is found quite frequently in urinary\n calculi (stones). The CHPD crystals were grown by the single diffusion gel grow\nth technique in sodium metasilicate gel (https://link.springer.com/article/10.1\n007/s10973-008-9841-1)\n\n
\n? Skipper A, Coltman A, Tomesko J, et al. Position of the Academy of Nutrition a\nnd Dietetics: Malnutrition (Undernutrition) Screening Tools for All Adults. J Ac\nad Nutr Diet. Apr 2020;120(4):709-713. doi:10.1016/j.jand.2019.09.011 Used with \nPermission\n\n
\nValidated screening tool for risk malnutrition completed by a nursing profession\nal or registered dietary nutritionist (RDN) in the acute inpatient setting.\n\n
\nhttps://www.mayocliniclabs.com/test-catalog/Overview/36670#Overview\n\n
\n? Skipper A, Coltman A, Tomesko J, et al. Position of the Academy of Nutrition a\nnd Dietetics: Malnutrition (Undernutrition) Screening Tools for All Adults. J Ac\nad Nutr Diet. Apr 2020;120(4):709-713. doi:10.1016/j.jand.2019.09.011 Used with \nPermission\n\n
\nThis test is a quantitative determination of Xylazine present in urine. A linea\nr calibration curve with LOD , cut-off, and ULOL generated for the analyte.\n\n
\nTest for presence of Xylazine in urine.\n\n
\nThis test is a quantitative determination of Xylazine present in urine.\n\n
\nTest for presence of 2,6-dimethylaniline in urine.\n\n
\nThis test is a quantitative determination of 2,6-dimethylaniline present in uri\nne.\n\n
\nThis test is a quantitative determination of 2,6-dimethylaniline present in uri\nne.\n\n
\n? 2020, Nutrition Terminology Reference Manual (eNCPT): Dietetics Language for N\nutrition Care. Academy of Nutrition and Dietetics. Used with permission\n\n
\nValidated nutrition assessment tool for malnutrition conducted by a registered d\nietitary nutritionist (RDN) in the acute inpatient setting.\n\n
\nThe ECMO device oxygen delivery setting.\n\n
\nImplant card (IC) offers patients easy access to all relevant information concer\nning the implanted device . The implant card identifies the implanted device, a\nllows access to safety-related information, identifies special care/needs requir\ned such as during security checks, and inform emergency clinical staff or first \nresponders. https://health.ec.europa.eu/\n\n
\nRelease of information request is a prompt to initiate the release of informatio\nn but not exclusive to patient information.\n\n
\nThis is an screening assay of esophageal cancer by the retrieval of samples ob\ntained using a non-endoscopic swallowable balloon from the distal esophageal mu\ncosa. The test is positive if either VIM and CCNA1 DNA methylation biomarkers a\nre present.\n\n
\n? 1989, Children's Hospital of Eastern Ontario. Used with permission.\n\n
\nInterpretation of the total score: Score 0 = no pain. Score 1-3 = mild pain \nScore 4-5 = moderate pain Score 6-7 = severe pain Limitation: A falsely low sc\nore may be seen in an infant who is too premature, ill to respond, or who is ve\nnted and receiving a paralyzing agent.\n\n
\n? 1989, Children's Hospital of Eastern Ontario. Used with permission.\n\n
\nThe Neonatal Infant Pain Scale (NIPS) is a behavioral pain scale that was develo\nped by the Children's Hospital of Eastern Ontario. It can be utilized with both\n full-term and pre-term infants. CHEO recommends use in neonates/infants less t\nhan 2 months of age, but the scale can be used up to 1 year of age. The tool wa\ns adapted from the CHEOPS scale (used for children between one and seven years) \nand is based on the behaviors that nurses have described as being indicative of \ninfant pain or distress. It is composed of six indicators. The infant should b\ne observed for one minute in order to fully assess each indicator.\n\n
\nNew "Breathing Pattern" that is reusable Score of 0: Relaxed--Usual pattern \nfor this baby Score of 1: Change in breathing--Indrawing, irregular, faster tha\nn usual, gagging, breath holding\n\n
\nScore of 0: Sleeping/Awake--Quiet, peaceful, sleeping or alert and settles Scor\ne of 1: Fussy--Alert, restless, and thrashing\n\n
\n? 1989, Children's Hospital of Eastern Ontario. Used with permission.\n\n
\nTotal score is the sum of points for the 6 parameters; the sum will be a minimum\n of zero (0) and a maximum of seven (7).\n\n
\n? 1989, Children's Hospital of Eastern Ontario. Used with permission.\n\n
\nScore of 0: Relaxed/Restrained--No muscular rigidity occasional random movements\n of arms Score of 1: Flexed/Extended--Tense, straight arms, rigid and/or rapid\n extension, flexion\n\n
\n? 1989, Children's Hospital of Eastern Ontario. Used with permission.\n\n
\nFoundation Pain Index (FPI) is a multi-analyte assay with algorithmic analysis (\nMAAA) that improves patient outcomes by identifying underlying, treatable causes\n of pain. FPI assists providers in identifying underlying determinants of pain w\nhile simultaneously indicating personalized, non-opioid pain therapies. The pain\n index is reported as a singular numerical score on a scale of 1-100 which is fu\nrther classified into categories representing the likelihood that detected bioch\nemical abnormalities are indeed a determinant or cause of pain.\n\n
\nThrombelastography determination of time to initial clot formation (reaction tim\ne or R), stimulated with kaolin.\n\n
\nIn thromboelastography, clot formation time (K) is the time for clot firmness to\n increase from 2mm (R) to 20 mm.\n\n
\nThrombelastography determination of clot strength, stimulated with kaolin\n\n
\nThrombelastography determination of time to initial clot formation (reaction tim\ne or R), stimulated with kaolin.\n\n
\nThrombelastography determination of kinetics of clot development, stimulated wit\nh kaolin and heparinase added\n\n
\nThrombelastography determination of clot initiation, stimulated by kaolin, and w\nith heparinase to neutralize heparin effect.\n\n
\nThe Primary Care PTSD Screen for DSM-5 (PC-PTSD-5) is a 5-item screen designed t\no identify individuals with probable PTSD. Those screening positive require fur\nther assessment, preferably with a structured interview.\n\n
\nTransmissible spongiform encephalopathies (TSEs or prion diseases) are a rare gr\noup of invariably fatal neurodegenerative disorders that affect humans and other\n mammals. TSEs are protein misfolding diseases that involve the accumulation of \nan abnormally aggregated form of the normal host prion protein (PrP). They are u\nnique among protein misfolding disorders in that they are transmissible and have\n different strains of infectious agents that are associated with unique phenotyp\nes in vivo. https://pubmed.ncbi.nlm.nih.gov/19157856/#:~:text=Abstract,host%20p\nrion%20protein%20(PrP).\n\n
\nROS1 rearrangement characterizes a small subset (1%-2%) of non-small cell lung c\nancer and is associated with slight/never smoking patients and adenocarcinoma hi\nstology. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5508815/]\n\n
\nTo date, the gold standard method to evaluate the GCN of MET is fluorescence in \nsitu hybridization (FISH). However, next-generation sequencing (NGS) is becoming\n more relevant to optimize therapy by revealing the mutational profile of each N\nSCLC. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8508248/]\n\n
\nA "polygenic risk score" is one way by which people can learn about their risk o\nf developing a disease, based on the total number of changes related to the dise\nase. [https://www.genome.gov/Health/Genomics-and-Medicine/Polygenic-risk-scores\n]\n\n
\nCarboxy THC is the major metabolite of cannabinoid found in urine, but is not re\nlated to source, time of exposure, amount, or impairment. Carboxy THC may be fou\nnd in urine for 7-10 days following light or moderate use and as long as 4-6 wee\nks following heavy use. THC metabolites are stored rapidly in body fat following\n use and are released slowly over time. [https://www.ncbi.nlm.nih.gov/pmc/articl\nes/PMC3196989/]\n\n
\nThe American College of Surgeons (ACS) is now disseminating and implementing syn\noptic operative reports for cancer surgery to improve accuracy and completeness \nof cancer surgery documentation.\n\n
\nThe American College of Surgeons (ACS) is now disseminating and implementing syn\noptic operative reports for cancer surgery to improve accuracy and completeness \nof cancer surgery documentation.\n\n
\nThe American College of Surgeons (ACS) is now disseminating and implementing syn\noptic operative reports for cancer surgery to improve accuracy and completeness \nof cancer surgery documentation.\n\n
\nThe American College of Surgeons (ACS) is now disseminating and implementing syn\noptic operative reports for cancer surgery to improve accuracy and completeness \nof cancer surgery documentation.\n\n
\nThe American College of Surgeons (ACS) is now disseminating and implementing syn\noptic operative reports for cancer surgery to improve accuracy and completeness \nof cancer surgery documentation.\n\n
\nA FHIR documentation request from payer and providers using a questionnaire for\n administrative and clinical data exchange.\n\n
\nHLA Order Panels. Need to keep the system as Bld/Tiss for 3LRD and PLRD since th\nis LOINC code will also be used for the HLA panels that are specific to the reci\npient results- much how like how we modeled recent HLA panels.\n\n
\nThe analysis of pediatric patients with acute myeloid leukemia (AML) bone marro\nw and peripheral blood specimens for classic rearrangements and chromosomal copy\n number changes.\n\n
\nThis panel contains terms to report the measurement of Vitamin B3 compounds and \nNicotinuric acid, a metabolite of B3.\n\n
\nTransplantation is an effective treatment of many clinical disorders, but the me\nchanisms that regulate immunological tolerance are uncertain and remain central \nto improving patient outcome. Hemopoietic stem cell transplantation (SCT) often \nestablishes "mixed chimerism" in which immune cells from both the donor and pati\nent coexist in vivo in a setting of immunological tolerance. [PMID:30824417]\n\n
\nChimerism analysis is the detection of specific genetic differences that disting\nuish between hematopoietic blood and marrow transplant.\n\n
\nQualitative detection of SARS coronavirus 2 (SARS-CoV-2) in respiratory specimen\ns by nucleic acid amplification with probe-based detection. Results may be based\n on multiple assays to determine the presence of the virus in a specimen.\n\n
\nThis term is created for but not restricted in use to the cobas? MPX-E test, wh\nich is FDA-approved qualitative in vitro nucleic acid screening test for human i\nmmunodeficiency virus type 1 (HIV-1) RNA (HIV-1 Group M & Group O RNA), HIV-2 RN\nA, hepatitis B virus (HBV) RNA, hepatitis C virus (HCV) RNA, hepatitis E virus (\nHEV) RNA in specimens from individual donors. This test is intended for determi\nning the eligibility of donors and is not intended for clinical or diagnostic ev\naluation of patients.\n\n
\nAngiography with fluorescein of the posterior segment of both eyes (OU) Exa\nmine the circulation of the retina and choroid using a fluorescent dye and spec\nialized camera. It is used to help diagnose specific eye diseases.\n\n
\nThis term is for the confirmation of manufacturer, packer, or distributor listi\nng their cosmetic product with the FDA in accordance with section 609(a) of the\n FD&C Act or section 4(a) of the Fair Packaging and Labeling Act.\n\n
\nThis term is for the confirmation of manufacturers and processors registering th\neir facilities with FDA .\n\n
\nA clinical note including documentation of a comprehensive foot examimnation and\n interpretation.\n\n
\nA clinical note including documentation of a retinal eye examination and interpr\netation.\n\n
\nThis test is for culturing amniocytes for prenatal genetic testing Fetal cells \nobtained by amniocentesis to be used to produce amniocyte cultures that can be \nused for genetic analysis\n\n
\nThe direct antiglobulin test is used to detect the presence of antibodies or com\nplement proteins bound to the surface of red blood cells. It is primarily utiliz\ned in the diagnosis of immune-mediated hemolytic anemias and transfusion reactio\nns. [PMID: 22566278]\n\n
\nThis test identifies the MRSA molecular typing. The MLVA type identifies the ty\npe of staphylococcus aureus strain using variable-number tandem repeat (VNTR) lo\nci. are regions of coding and non-coding nucleotide repeats that are adjacent \nto each other and that vary in number This different microorganisms. Analysis o\nf VNTR is the basis for MLVA (multilocus VNTR analysis)\n\n
\nEvaluation of the most common tick-borne diseases found in the United States, in\ncluding Lyme disease, human monocytic and granulocytic ehrlichiosis, and babesio\nsis using the modified 2-tier testing algorithm approach.\n\n
\nTesting performed on urine specimens for the presence and quantitation of carbam\nazepine epoxide (a urinary metabolite of carbamazepine) in order to determine re\ncent use of products containing carbamazepine.\n\n
\nSulbactam-durlobactam (SUL-DUR), formerly ETX2514SUL, is a novel ?-lactam-?-lact\namase inhibitor designed specifically for the treatment of CRAB infections\n\n
\nA test referring to the sample being a trough plasma or serum sample in order to\n test for drugs taken once a day and the sample drawn 24 hours after the last do\nse. [PMID: 18235115]\n\n
\nA test referring to the sample being a trough plasma or serum sample in order to\n test for drugs taken once a day and the sample drawn 24 hours after the last do\nse.\n\n
\nA test referring to the sample being a trough plasma or serum sample in order to\n test for drugs taken once a day and the sample drawn 24 hours after the last do\nse.\n\n
\nA test referring to the sample being a trough plasma or serum sample in order to\n test for drugs taken once a day and the sample drawn 24 hours after the last do\nse.\n\n
\nA test referring to the sample being a trough plasma or serum sample in order to\n test for drugs taken once a day and the sample drawn 24 hours after the last do\nse.\n\n
\nA test referring to the sample being a trough plasma or serum sample in order to\n test for drugs taken once a day and the sample drawn 24 hours after the last do\nse.\n\n
\nA test referring to the sample being a trough plasma or serum sample in order to\n test for drugs taken once a day and the sample drawn 24 hours after the last do\nse.\n\n
\nhttps://diagnostics.roche.com/global/en/products/params/cobas-hbv-rna-ruo.html#:\n~:text=cobas%C2%AE%20HBV%20RNA%20is%20a%20quantitative%20automated%20real%2Dtime\n,and%20serum%20of%20infected%20specimens.\n\n
\nDetection of neoplastic clone associated with the chromosome abnormalities seen \nin small lymphocytic lymphoma and other low-grade B-cell lymphomas.\n\n
\nhttps://miravistalabs.com/medical-fungal-infection-testing/antigen-detection/coc\ncidioides-quantitative-eia-test/#:~:text=The%20MVista%C2%AE%20coccidioides%20qua\nntitative,stopped%20and%20to%20diagnose%20relapse.\n\n
\nAtomoxetine (Strattera(R)) is a selective norepinephrine (noradrenaline) reuptak\ne inhibitor that is not classified as a stimulant, and is indicated for use in p\natients with attention-deficit hyperactivity disorder (ADHD).\n\n
\n4-hydroxy Atomoxetine is a metabolite of the norepinephrine transporter (NET) in\nhibitor atomoxetine (Item No. 22248). It is formed from atomoxetine by the cytoc\nhrome P450 (CYP) isoform CYP2D6 in human liver microsomes.\n\n
\nEntamoeba coli is one of many non-pathogenic protozoa found in humans. It is tra\nnsmitted through fecal-oral contact, and the mature cyst can be found in contami\nnated water. Typically, these protozoa inhabit the large intestinal tract and ca\nn be identified in diagnostic stool specimens. This assay is for detection of En\ntamoeba coli by using DNA obtained from stool samples by PCR method.\n\n
\nSalmonella, Shigella, and Campylobacter species are the most common causes of ac\nute bacterial enteritis in the United States\n\n
\nImmunoassay for measuring the in vitro quantitative determination of sTREM-1 in \nhuman plasma.\n\n
\nCopyright ? Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer\n, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant fr\nom Pfizer Inc. No permission required to reproduce, translate, display or distri\nbute.\n\n
\nCopyright ? Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer\n, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant fr\nom Pfizer Inc. No permission required to reproduce, translate, display or distri\nbute.\n\n
\nCopyright ? Pfizer Inc. All rights reserved. Developed by Drs. Robert L. Spitzer\n, Janet B.W. Williams, Kurt Kroenke and colleagues, with an educational grant fr\nom Pfizer Inc. No permission required to reproduce, translate, display or distri\nbute.\n\n
\n? 2006 Morris et al. Used with permission\n\n
\nEntamoeba hartmanni is a non-pathogenic amoeba with world wide distribution. Its\n life cycle is similar to that of E. histolytica but it does not have an invasiv\ne stage and does not ingest red blood cells.\n\n
\nSuvorexant is a hypnotic drug with a novel mechanism of action. The drug produce\ns rapid onset of sleep by inhibiting the orexin neurons of the arousal system, p\nromoting decreased wakefulness. Suvorexant is a potent and highly selective dual\n orexin receptor antagonist. [PMID: 28035034}\n\n
\nThis profile evaluates for hereditary (congenital) causes of dyserythropoietic a\nnemia\n\n
\nTest is useful for Providing a comprehensive genetic evaluation for patients wit\nh a personal or family history suggestive of Epstein-Barr virus (EBV) susceptibi\nlity or a heritable predisposition to lymphoproliferative disease Establishi\nng a diagnosis of a hereditary form of EBV susceptibility or a related disorder,\n allowing for appropriate management and surveillance for disease features based\n on the gene or variant involved Identifying variants within genes known to b\ne associated with heritable EBV susceptibility and/or lymphoproliferative diseas\ne, allowing for predictive testing of at-risk family members\n\n
\nHuman papilloma virus 16 & 18+45 mRNA\n\n
\n2014 ? Nadelson, L., Jorcyk, C., Yang, D., Jarratt Smith, M., Matson, S., Cornel\nl, K., & Husting, V. (2014). I just don't trust them: the development and valida\ntion of an assessment instrument to measure trust in science and scientists. Sch\nool Science and Mathematics, 114(2), 76-86. Used with permission\n\n
\n2014 ? Nadelson, L., Jorcyk, C., Yang, D., Jarratt Smith, M., Matson, S., Cornel\nl, K., & Husting, V. (2014). I just don't trust them: the development and valida\ntion of an assessment instrument to measure trust in science and scientists. Sch\nool Science and Mathematics, 114(2), 76-86. Used with permission\n\n
\n2014 ? Nadelson, L., Jorcyk, C., Yang, D., Jarratt Smith, M., Matson, S., Cornel\nl, K., & Husting, V. (2014). I just don't trust them: the development and valida\ntion of an assessment instrument to measure trust in science and scientists. Sch\nool Science and Mathematics, 114(2), 76-86. Used with permission\n\n
\n2014 ? Nadelson, L., Jorcyk, C., Yang, D., Jarratt Smith, M., Matson, S., Cornel\nl, K., & Husting, V. (2014). I just don't trust them: the development and valida\ntion of an assessment instrument to measure trust in science and scientists. Sch\nool Science and Mathematics, 114(2), 76-86. Used with permission\n\n
\n2014 ? Nadelson, L., Jorcyk, C., Yang, D., Jarratt Smith, M., Matson, S., Cornel\nl, K., & Husting, V. (2014). I just don't trust them: the development and valida\ntion of an assessment instrument to measure trust in science and scientists. Sch\nool Science and Mathematics, 114(2), 76-86. Used with permission\n\n
\n2014 ? Nadelson, L., Jorcyk, C., Yang, D., Jarratt Smith, M., Matson, S., Cornel\nl, K., & Husting, V. (2014). I just don't trust them: the development and valida\ntion of an assessment instrument to measure trust in science and scientists. Sch\nool Science and Mathematics, 114(2), 76-86. Used with permission\n\n
\n2014 ? Nadelson, L., Jorcyk, C., Yang, D., Jarratt Smith, M., Matson, S., Cornel\nl, K., & Husting, V. (2014). I just don't trust them: the development and valida\ntion of an assessment instrument to measure trust in science and scientists. Sch\nool Science and Mathematics, 114(2), 76-86. Used with permission\n\n
\n2014 ? Nadelson, L., Jorcyk, C., Yang, D., Jarratt Smith, M., Matson, S., Cornel\nl, K., & Husting, V. (2014). I just don't trust them: the development and valida\ntion of an assessment instrument to measure trust in science and scientists. Sch\nool Science and Mathematics, 114(2), 76-86. Used with permission\n\n
\n2014 ? Nadelson, L., Jorcyk, C., Yang, D., Jarratt Smith, M., Matson, S., Cornel\nl, K., & Husting, V. (2014). I just don't trust them: the development and valida\ntion of an assessment instrument to measure trust in science and scientists. Sch\nool Science and Mathematics, 114(2), 76-86. Used with permission\n\n
\n2014 ? Nadelson, L., Jorcyk, C., Yang, D., Jarratt Smith, M., Matson, S., Cornel\nl, K., & Husting, V. (2014). I just don't trust them: the development and valida\ntion of an assessment instrument to measure trust in science and scientists. Sch\nool Science and Mathematics, 114(2), 76-86. Used with permission\n\n
\n2014 ? Nadelson, L., Jorcyk, C., Yang, D., Jarratt Smith, M., Matson, S., Cornel\nl, K., & Husting, V. (2014). I just don't trust them: the development and valida\ntion of an assessment instrument to measure trust in science and scientists. Sch\nool Science and Mathematics, 114(2), 76-86. Used with permission\n\n
\n2014 ? Nadelson, L., Jorcyk, C., Yang, D., Jarratt Smith, M., Matson, S., Cornel\nl, K., & Husting, V. (2014). I just don't trust them: the development and valida\ntion of an assessment instrument to measure trust in science and scientists. Sch\nool Science and Mathematics, 114(2), 76-86. Used with permission\n\n
\n2014 ? Nadelson, L., Jorcyk, C., Yang, D., Jarratt Smith, M., Matson, S., Cornel\nl, K., & Husting, V. (2014). I just don't trust them: the development and valida\ntion of an assessment instrument to measure trust in science and scientists. Sch\nool Science and Mathematics, 114(2), 76-86. Used with permission\n\n
\n2014 ? Nadelson, L., Jorcyk, C., Yang, D., Jarratt Smith, M., Matson, S., Cornel\nl, K., & Husting, V. (2014). I just don't trust them: the development and valida\ntion of an assessment instrument to measure trust in science and scientists. Sch\nool Science and Mathematics, 114(2), 76-86. Used with permission\n\n
\n2014 ? Nadelson, L., Jorcyk, C., Yang, D., Jarratt Smith, M., Matson, S., Cornel\nl, K., & Husting, V. (2014). I just don't trust them: the development and valida\ntion of an assessment instrument to measure trust in science and scientists. Sch\nool Science and Mathematics, 114(2), 76-86. Used with permission\n\n
\n2014 ? Nadelson, L., Jorcyk, C., Yang, D., Jarratt Smith, M., Matson, S., Cornel\nl, K., & Husting, V. (2014). I just don't trust them: the development and valida\ntion of an assessment instrument to measure trust in science and scientists. Sch\nool Science and Mathematics, 114(2), 76-86. Used with permission\n\n
\n2014 ? Nadelson, L., Jorcyk, C., Yang, D., Jarratt Smith, M., Matson, S., Cornel\nl, K., & Husting, V. (2014). I just don't trust them: the development and valida\ntion of an assessment instrument to measure trust in science and scientists. Sch\nool Science and Mathematics, 114(2), 76-86. Used with permission\n\n
\n2014 ? Nadelson, L., Jorcyk, C., Yang, D., Jarratt Smith, M., Matson, S., Cornel\nl, K., & Husting, V. (2014). I just don't trust them: the development and valida\ntion of an assessment instrument to measure trust in science and scientists. Sch\nool Science and Mathematics, 114(2), 76-86. Used with permission\n\n
\n2014 ? Nadelson, L., Jorcyk, C., Yang, D., Jarratt Smith, M., Matson, S., Cornel\nl, K., & Husting, V. (2014). I just don't trust them: the development and valida\ntion of an assessment instrument to measure trust in science and scientists. Sch\nool Science and Mathematics, 114(2), 76-86. Used with permission\n\n
\n2014 ? Nadelson, L., Jorcyk, C., Yang, D., Jarratt Smith, M., Matson, S., Cornel\nl, K., & Husting, V. (2014). I just don't trust them: the development and valida\ntion of an assessment instrument to measure trust in science and scientists. Sch\nool Science and Mathematics, 114(2), 76-86. Used with permission\n\n
\n2014 ? Nadelson, L., Jorcyk, C., Yang, D., Jarratt Smith, M., Matson, S., Cornel\nl, K., & Husting, V. (2014). I just don't trust them: the development and valida\ntion of an assessment instrument to measure trust in science and scientists. Sch\nool Science and Mathematics, 114(2), 76-86. Used with permission\n\n
\n2014 ? Nadelson, L., Jorcyk, C., Yang, D., Jarratt Smith, M., Matson, S., Cornel\nl, K., & Husting, V. (2014). I just don't trust them: the development and valida\ntion of an assessment instrument to measure trust in science and scientists. Sch\nool Science and Mathematics, 114(2), 76-86. Used with permission\n\n
\nWarden, V, Hurley AC, Volicer, V. (2003). Development and psychometric evaluatio\nn of the Pain Assessment in Advanced Dementia (PAINAD) Scale. J Am Med Dir Assoc\n, 4:9-15. Developed at the New England Geriatric Research Education & Clinical C\nenter, Bedford VAMC, MA.\n\n
\n1. No need to console is characterized by a sense of well-being. The person appe\nars content. 2. Distracted or reassured by voice or touch is characterized by a\n disruption in the behavior when the person is spoken to or touched. The behavi\nor stops during the period of interaction, with no indication that the person is\n at all distressed. 3. Unable to console, distract, or reassure is characteriz\ned by the inability to soothe the person or stop a behavior with words or actio\nns. No amount of comforting, verbal or physical, will alleviate the behavior.\n\n
\n1. None is characterized by speech or vocalization that has a neutral or pleasan\nurmuring sounds, wails, or laments in much louder than usual volume. Loud groan\ning is characterized by louder than usual inarticulate involuntary sounds, often\n abruptly beginning and ending. 6. Crying is characterized by an utterance of e\nmotion accompanied by tears. There may be sobbing or quiet weeping.\nt quality. 2. Occasional moan or groan is characterized by mournful or murmurin\ng sounds, wails, or laments. Groaning is characterized by louder than usual inar\nticulate involuntary sounds, often abruptly beginning and ending. 3. Low level \nspeech with a negative or disapproving quality is characterized by muttering, mu\nmbling, whining, grumbling, or swearing in a low volume with a complaining, sarc\nastic, or caustic tone. 4. Repeated troubled calling out is characterized by ph\nrases or words being used over and over in a tone that suggests anxiety, uneasin\ness, or distress. 5. Loud moaning or groaning is characterized by mournful or m\n\n
\n1. Relaxed is characterized by a calm, restful, mellow appearance. The person se\ntight and inflexible. The trunk may appear straight and unyielding. (Exclude an\ny contractures.) 6. Fists clenched is characterized by tightly closed hands. Th\ney may be opened and closed repeatedly or held tightly shut. 7. Knees pulled up\n is characterized by flexing the legs and drawing the knees up toward the chest.\n An overall troubled appearance. (Exclude any contractures.) 8. Pulling or push\ning away is characterized by resistiveness upon approach or to care. The person \nis trying to escape by yanking or wrenching him- or herself free or shoving you \naway. 9. Striking out is characterized by hitting, kicking, grabbing, punching,\n biting, or other form of personal assault.\nems to be taking it easy. 2. Tense is characterized by a strained, apprehensive\n, or worried appearance. The jaw may be clenched. (Exclude any contractures.) 3\n. Distressed pacing is characterized by activity that seems unsettled. There may\n be a fearful, worried, or disturbed element present. The rate may be faster or \nslower. 4. Fidgeting is characterized by restless movement. Squirming about or \nwiggling in the chair may occur. The person might be hitching a chair across the\n room. Repetitive touching, tugging, or rubbing body parts can also be observed.\n 5. Rigid is characterized by stiffening of the body. The arms and/or legs are \n\n
\nPSi (Patient State index) is a processed EEG parameter related to the effect of \nanesthetic agents provided during neurosurgery and major back surgery. PSI ha\ns no units and ranges from 0 (fully suppressed EEG) to 100 (consistent with full\ny awake). Most values are with the 15 to 85 range\n\n
\nThis is an AI-based probability calculation of whether pneumonia is present. Thi\ns term was created for pneumonia probability calculated by a machine learning/co\nmputer vision algorithm. The value is calculated from the chest radiograph and i\ns combined with other test results to decide whether the patient should be treat\ned for pneumonia.\n\n
\nAlpha-globin is an essential component of the hemoglobin tetramer, starting from\nse gel electrophoresis of the amplification products.\n the early stages of embryonic development. Deletion mutations involving one or\n both of the two alpha-globin genes (alpha1 and alpha2, located on chromosome 16\np13) lead to reduced production of alpha-globin chains, and are the major cause\n of alpha-thalassemia. Severity of the disease is dependent on the total copy nu\nmber of functional alpha-globin genes remaining. This assay detects the seven m\nost common deletions (-alpha3.7, -alpha4.2, -alpha20.5, --SEA, --MED, -FIL, and \n--THAI) found in patients with alpha-thalassemia. This assay is performed by all\nele-specific PCR amplification of deletion mutation fragments, followed by agaro\n\n
\nAdvanced paternal age was found to be associated with an increased risk of misca\nrriage. PMID[32358607]\n\n
\nEarly mobilization appears to decrease the incidence of ICU-AW, improve the func\ntional capacity, and increase the number of ventilator-free days and the dischar\nged-to-home rate for patients with a critical illness in the ICU setting. PMID[3\n1581205]\n\n
\nThis term reports that an ultrasound was performed for a birth registry.\n\n
\n2014 ? Nadelson, L., Jorcyk, C., Yang, D., Jarratt Smith, M., Matson, S., Cornel\nl, K., & Husting, V. (2014). I just don't trust them: the development and valida\ntion of an assessment instrument to measure trust in science and scientists. Sch\nool Science and Mathematics, 114(2), 76-86. Used with permission\n\n
\n? 2012 AHI of Indiana. Used with permission.\n\n
\n? 2012 AHI of Indiana. Used with permission.\n\n
\n? 2012 AHI of Indiana. Used with permission.\n\n
\n? 2012 AHI of Indiana. Used with permission.\n\n
\n? 2012 AHI of Indiana. Used with permission.\n\n
\n? 2012 AHI of Indiana. Used with permission.\n\n
\n? 2012 AHI of Indiana. Used with permission.\n\n
\n? 2012 AHI of Indiana. Used with permission.\n\n
\n? 2012 AHI of Indiana. Used with permission.\n\n
\n? 2012 AHI of Indiana. Used with permission.\n\n
\n? 2012 AHI of Indiana. Used with permission.\n\n
\nThe 10-m walk test (10MWT) is to measure of gait speed in Parkinson's disease (P\nD). This test is a performance measure used to assess walking speed in meters p\ner second over a short distance; to determine functional mobility, gait, and ves\ntibular function\n\n
\nThis term reports that an ultrasound was performed for a birth registry.\n\n
\nUsed by multiple provincial facilities\n\n
\nUsed by multiple provincial facilities\n\n
\nUsed by multiple provincial facilities\n\n
\nUsed by multiple provincial facilities\n\n
\nUsed by multiple provincial facilities\n\n
\nThis submission includes questions that were developed to investigate psychologi\ncal and social aspects as part a COVID-19 study conducted in the European ORCHES\nTRA project and lead by colleagues in work package 3 of said project.\n\n
\nThis test is evaluate enzymatic activity to ruling out mucopolysaccharidosis typ\nes II, IIIA, IIIB, IIIC, IIID, IVA, IVB, VI, VII.\n\n
\nThis term is for a test is to rule out multiple sulfatase deficiency i.e., iduro\nnate-2- sulfatase, heparan-N-sulfatase, N-acetylgalactosamine-6-sulfatase, N-ace\ntylglucosamine-6-sulfatase,\n\n
\nFormalin-fixed paraffin embedded (FFPE) breast tumor tissue 16 cancer-related ge\nnes:ER, PGR, BCL2, SCUBE2, Ki-67, MYBL2, Survivin, Cyclin B1, STK15, HER2, GRB7,\n Stromelysin 3, Cathepsin L2, GSTM1, BAG1, and CD685 reference genes:Beta-actin,\n GAPDH, G\n\n
\nThis submission includes questions that were developed to investigate psychologi\ncal and social aspects as part a COVID-19 study conducted in the European ORCHES\nTRA project and lead by colleagues in work package 3 of said project.\n\n
\nThis term was created for, but not limited in use to, the Alinity High Risk HPV \ntest kit which detects 14 HR HPV genotypes (HPV 16, 18, 31, 33, 35, 39, 45,51, 5\n2, 56, 58, 59, 66, and 68) is achieved through a primer mix targeting a conserve\nd region of the HPV genomes and single stranded DNA probes. This test identifies\n high-risk (HR) HPV types 16, 18, 45, while reporting the concurrent detection o\nf the other HR genotypes (31/33/52/58) and (35/39/51/56/59/66/68). This test is \nindicated for use in routine cervical cancer screening.\n\n
\nFrequency of condition or symptom occurrence as reported\n\n
\nAssociated Precondition describes the previously existing conditions or states t\nhat could affect a measurement or assessment. For example, blood pressure taken\n while standing or lying down; or whether the assessment is during activity or a\nt rest\n\n
\nThis term reports that an ultrasound was performed for a birth registry\n\n
\nActive medication list is a list of medications that a patient is currently take\nn. This list is inclusive of current prescription, otc, or administered medicat\nions\n\n
\nReconciled medication list is a list of medications that have been reconciled an\nd identified as current medication list\n\n
\nDischarged medication list is a list of medications that a patient is discharged\n on after a hospital admission\n\n
\nPatient generated medication list is a list of medications that is a patient may\n given during a patient interview with a provider in oral or written form.\n\n
\nMedication list that are private and need patient consent to share are medicatio\nns that are used for substance abuse.\n\n
\nMedication administration list is a list of medications administered via iv/im/s\nubcutaneously to a patient in a pharmacy, clinic, or hospital setting.\n\n
\nMedication list for public health and CDC reporting are generally immunizations \nthat administered to a patient and that providers are required to report.\n\n
\nA transfer medication list is in the discharge summary that contains the dischar\nged medication list and used when transferring within a hospital from one level \nof care to another (intersystem).\n\n
\nPatient reported description of how long the condition or symptom(s) occurs duri\nng a particular episode\n\n
\nThis test is for the nucleic acid amplification using primer-probe sets for dete\nction of gene rearrangements (FR1, FR2, FR3).\n\n
\nUsed by multiple provincial facilities\n\n
\nThis term certifies a temporary incapacity for work (CIT), authenticated by the \nstamp of the doctor and the health establishment or digitally signed by the doct\nor, and notified electronically to the social security services by the competent\n services of the public, private and social health care provider.\n\n
\nDevelopers of standardized pain assessment scales often use a total score betwee\nn zero and ten (0 - 10) to assess pain level. The clinician's interpretation of \nthe score is rarely included in the standardized assessment scale. This reusable\n pain scale score interpretation can be used in conjunction with the developer's\n pain assessment scale when the developer (or designated clinical subject matter\n expert) validates the answer list meaning is an exact match.\n\n
\nThis assay is used for assessing mephobarbital and phenobarbital levels in postm\nortem samples as an aid in investigating cause of death. Existing LOINC Codes u\nsed under this panel include: Mephobarbital, B (3750-7) and Phenobarbital, B (82\n970-5)\n\n
\nThe Job Insecurity measure is a measurement of the perceived stability of one's \ncurrent job and ability to find jobs with similar salary and benefits.\n\n
\nThe presence of a food swamp is calculated using the traditional Retail Food Env\nironment Index per county, which includes the number of fast food restaurants an\nd convenience stores divided by the number of grocery stores and supermarkets.\n\n
\nThe number of supermarkets and grocery stores in the county. Grocery stores incl\nude establishments generally known as supermarkets and smaller grocery stores pr\nimarily engaged in retailing a general line of food, such as canned and frozen f\noods.\n\n
\nThe number of limited-service restaurants in the county. Limited-service restaur\nants include establishments primarily engaged in providing food services where p\natrons generally order or select items and pay before eating.\n\n
\nThe number of convenience stores in the county. Establishments known as convenie\nnce stores or food marts are primarily engaged in retailing a limited line of go\nods that include soda, snack foods, etc.\n\n
\nThe patient can expect adherence to sterile technique, specific actions and acti\nvities to maintain sterility, will be followed during the operative or other inv\nasive procedure to prevent harm\n\n
\nThis term is for an alert, warn or call to a state of preparedness. or provide i\nnformation which is flagged to raise awareness of a potential danger to/from the\n subject of the International Patient Summary (IPS) or to/from another individua\nl or awareness of a potential obstacle to care. ISO 27269 HL7.org\n\n
\nSperm DNA damage can be defined as any chemical change in the normal structure o\nf the DNA. Among these changes, sperm DNA fragmentation (sDF) is one of the most\n common disturbances affecting the genetic material in the form of single or dou\nble strand breaks. sDF may be triggered by different processes, including the de\nfective packaging of the DNA during spermatogenesis, and processes of cell death\n and oxidative stress which may be associated with several pathological and envi\nronmental conditions.\n\n
\nData for red and green fluorescence are collected by flow cytometry and transfor\nmed to determine the degree of red fluorescence in the sperm population, known a\ns the DNA fragmentation index (DFI). DFI measures abnormal chromatin structure.\n\n
\nHigh DNA stainability measures the amount of sperm in a semen sample having incr\neased the amount of retained histones due to the lack of full protamination\n\n
\nThe Static Oxidation-Reduction Potential (sORP) Test represents the overall bala\nnce between oxidants and antioxidants, thereby providing a measure of the oxidat\nive stress in a biologic sample.\n\n
\nThis test is a specific immunological test that measures the level of Immunoglob\nulin E (IgE) antibodies against cobalt in a person's blood serum. IgE antibodies\n are produced by the immune system in response to exposure to certain allergens \nor substances, and their presence indicates an allergic reaction. This test is \nused to help diagnose occupational asthma or other respiratory allergic conditio\nns caused by exposure to cobalt, which is a low molecular weight agent commonly \nfound in various industrial and manufacturing settings.[PMID 7939614]\n\n
\nThis term is for the assay of Glucosylceramide (GL-1) biomarker level for Gauche\nr and Fabry patients.. A high sensitivity plasma GL-1 assay with LLOQ at 0.1 ?g/\nmL was developed and validated using delipidized plasma so that patient plasma c\noncentrations that are below normal reference range can be measured accurately. \n[PMID:27547732}\n\n
\nThe reason given explaining why a substitute medication was not provided.\n\n
\nReasons or conditions that warrant the prescription or administration of a medic\nation.\n\n
\nThe textual representation of a medication, either brand name, manufacturer name\n, or other\n\n
\nThe length of time between an initial observance of an instruction and a subsequ\nent, repeat observance of the same instruction.\n\n
\nA reason that validates a medication, test, procedure, or clinical action.\n\n
\nThe part a medication is playing in concert with other medications; therapeutic,\n adjuvant, or excipient.\n\n
\nThe medication safety guidance that has been overridden.\n\n
\nAn indicator that an exception exists that allows the medication safety limits t\no be overridden.\n\n
\nThe total number of times a medication may be administered to the patient.\n\n
\nThe rules, guidelines, or other instructions that aid a clinician in prescribing\n or administering a medication.\n\n
\nThe attributes that need to exist in order to cease administration of a medicati\non.\n\n
\nThe basis for a medication prescription.\n\n
\nThe date and time a medication request is to end.\n\n
\nOccurring attributes that will initiate a review of an administration.\n\n
\nThe numerical representation for a request for medication, service, procedure, o\nr other action.\n\n
\nDirections provided to a pharmacy for how a medication is to be dispensed.\n\n
\nThe combination of doses throughout a one-day period that are deemed to be neede\nd for treatment.\n\n
\nA test for Parainfluenza virus 2 RNA in any specimen. A parent code for those w\nith pre-coordinated specimens.\n\n
\nThe basis that allows the prescription or administration of a medication beyond \nits safe use.\n\n
\nThe highest dosage of a medication that may be administered safely.\n\n
\nA test for Schistocytes in blood via any light microscopy method. A parent code\n for those with pre-coordinated light microscopy methods.\n\n
\nA test for Neisseria gonorrhoeae rRNA in any specimen. A parent code for those \nwith pre-coordinated specimens.\n\n
\nThe date and time a request is to begin\n\n
\nA test for Hepatitis B virus core Ab.IgM in Ser/Plas via any immuno-assay method\n. A parent code for those with pre-coordinated immuno-assay methods.\n\n
\nSome medication administrations are ordered for a specific duration rather than \na number of doses. This indicates the amount of that duration that has been com\npleted as compared to the total ordered duration.\n\n
\nThe period of time over which a combined maximum dose of a medication may be saf\nely administered.\n\n
\nThe date on which a medication prescription may no longer be dispensed.\n\n
\nThe length of time a specific therapeutic instruction should take place.\n\n
\nA standard base excess in arterial blood used as a parent code for those with sp\necified methods.\n\n
\nA test for Beta globulin in serum or plasma via any electrophoresis method. A p\narent code for those with pre-coordinated electrophoresis methods.\n\n
\nThe reason a medication was prescribed, a procedure was performed, or other acti\nons were taken.\n\n
\nThe attributes that need to exist prior to the allowance of a substitute medicat\nion.\n\n
\nA test for Creatinine renal clearance. predicted in serum or plasma via any meth\nod. A parent code for those with pre-coordinated methods.\n\n
\nThe date and time that a medication administration was stopped.\n\n
\nThe urgency in which a medication must be dispensed for administration\n\n
\nThe reasons that justify administering a medication dosage.\n\n
\nThe amount of a medication that may be administered on a daily basis.\n\n
\nA test for Epstein Barr virus DNA in any specimen. A parent code for those with\n pre-coordinated specimens.\n\n
\nA base excess in venous cord blood used as a parent code for those with pre-coor\ndinated methods.\n\n
\nA test for Gamma globulin in serum or plasma via any method. A parent code for \nthose with pre-coordinated methods.\n\n
\nA test for the presence of Beta hydroxybutyrate in urine. This is a parent code\n for those with pre-coordinated methods.\n\n
\nThe narrative medication administration directions given in a format the is more\n easily parsed than string data type, i.e. xml, html, or other structured text.\n\n
\nThe date on which a medication may begin to be dispensed.\n\n
\nA numeric volume, mass, or count of a medication dose that may be safely adminis\ntered over a specific period.\n\n
\nA medication amount that is different from what is prescribed yet acceptable.\n\n
\nThe order in which therapeutic instructions need to take place.\n\n
\nThe strength of a medication presented as a ratio or fraction with a numerator a\nnd denominator.\n\n
\nThe fraction of red blood cells to total volume of blood\n\n
\n? 2006 PW Hellyer, SR Uhrig, NG Robinson. Used with permission.\n\n
\n? 2006 PW Hellyer, SR Uhrig, NG Robinson. Used with permission.\n\n
\nThis noninvasive RNA colorectal cancer screening test is intended for the qualit\native detection of colorectal neoplasia associated RNA markers and for the prese\nnce of occult hemoglobin in human stool for aiding in the detection of CRC & adv\nanced adenomas\n\n
\nQCT (quant CT) Spine [Mass/Volume] Bone Mineral Density\n\n
\nDXA-Equivalent Spine [T-score] Bone Mineral Density\n\n
\nQCT Total Hip [Mass/Area] Bone Mineral Density\n\n
\nQCT Total Hip [Mass/Area] Bone Mineral Density\n\n
\nQCT Total Hip [T-Score] Bone Mineral Density\n\n
\nQCT Total Hip [Z-Score] Bone Mineral Density\n\n
\nQCT Femoral Neck [Mass/Area] Bone Mineral Density\n\n
\nQCT Femoral Neck [Mass/Area] Bone Mineral Density\n\n
\nQCT Femoral Neck [T-Score] Bone Mineral Density\n\n
\nQCT Femoral Neck [Z-Score] Bone Mineral Density\n\n
\nThis term is a document completed by a qualified occupational health practitione\nr or an occupational medical practitioner that certifies employee's fitness for \nand suited to the work they are to do. The test done for a medical fitness certi\nficate are vision screening, drug & urine testing, lung function testing, audiom\netric testing and physical examination.\n\n
\nThis term is a certification document of mandatory screening of all drivers that\n need to renovate driver license\n\n
\nSubmission not requested with method. Generally test is done by LC/MS\n\n
\nElectronic cigarette status represents a person's smoking behavior using a elect\nronic nicotine delivery system. E-cigarettes do not contain tobacco, but many o\nf them contain nicotine. The Food and Drug Administration (FDA) classifies e-cig\ns as a "tobacco products."\n\n
\nThis term is for the Modernization of Cosmetics Regulation Act of 2022 (MoCRA) m\nanufacturers and processors must register their facilities with the FDA and rene\nw their registration every two years.\n\n
\nMagnetic resonance cholangiopancreatography\n\n
\nMagnetic resonance cholangiopancreatography with contrast IV\n\n
\nMR perfusion Brain with contrast IV\n\n
\nThe term represents the scoring method used in the PD-L1 IHC observations in HL7\n FHIR resource. It allows differentiation of the values to be produced in the sa\nme PD-L1 observation using different scoring methods, such as CPS, TPS, TC, TCE \n& IC.\n\n
\nThis term represents a measurement of PD-L1 expression, calculated as the number\n of PD-L1 staining cells (tumor cells, lymphocytes, macrophages) divided by the \ntotal number of viable tumor cells, multiplied by 100.\n\n
\nThis term represents a measurement of PD-L1 expression, calculated as the number\n of PD-L1 staining tumor cells divided by the total number of viable tumor cells\n, multiplied by 100.\n\n
\nThis term represents a measurement of PD-L1 expression in tumor-infiltrating im\nmune cells (IC), calculated as the proportion of tumor area that is occupied by \nPD-L1 staining IC of any intensity.\n\n
\n# Days with AQI - Number of days in the year having an Air Quality Index value. \nThis is the number of days on which measurements from any monitoring site in the\n county or MSA were reported to the Air Quality System (AQS) database.\n\n
\n? 2006 PW Hellyer, SR Uhrig, NG Robinson. Used with permission.\n\n
\nThe Colorado State Acute Pain Scale was developed at Colorado State University t\no provide an easy to use scale for the assessment of acute pain in veterinary pa\ntients\n\n
\nAI based clinical decision support on the ICU\n\n
\nAir toxics respiratory hazard index (the sum of hazard indices for those air tox\nics with reference concentrations based on respiratory endpoints, where each haz\nard index is the ratio of exposure concentration in the air to the health-based \nreference concentration set by EPA). EPA 2011 National Air Toxics Assessments\n\n
\nDiesel particulate matter level in air in micrograms per cubic meter (?g/m3). So\nurce: EPA 2011 National Air Toxics Assessments\n\n
\nParticulate matter (PM2.5) levels in air, micrograms per cubic meter (?g/m3) ann\nual average, 2012. Source: EPA Office of Air and Radiation\n\n
\nOzone summer seasonal avg. of daily maximum 8-hour concentration in air in parts\n per billion, 2012. Source: EPA Office of Air and Radiation\n\n
\nPercent of housing units built before 1960, as indicator of potential exposure t\no lead paint. Calculated from the Census Bureau's American Community Survey 2010\n-2014.\n\n
\nCount of vehicles per day (average annual daily traffic) at major roads within 5\n00 meters (or nearest one beyond 500 m), divided by distance in meters. Calculat\ned from U.S. Department of Transportation National Transportation Atlas Database\n, Highway Performance Monitoring System, 2014, retrieved 4/2015.\n\n
\nCount of RMP (potential chemical accident management plan) facilities within 5 k\nm (or nearest one beyond 5 km), each divided by distance in km. Calculated from \nEPA RMP database, retrieved 11/2015.\n\n
\nCount of TSDF (hazardous waste management facilities) within 5 km (or nearest on\ne beyond 5 km), each divided by distance in km. Calculated from EPA RCRAInfo dat\nabase, retrieved 11/2015.\n\n
\nCount of proposed and listed NPL sites within 5 km (or nearest one beyond 5 km),\n each divided by distance in km. Count excludes deleted sites. Source: Calculate\nd from EPA CERCLIS database, retrieved 11/2015.\n\n
\nCount of National Pollution Elimination Discharge System (NPDES) major direct wa\nter discharger facilities within 5 km (or nearest one beyond 5 km), each divided\n by distance in km. Calculated from EPA PCS/ICIS database, retrieved 12/2015.\n\n
\nThis term is proof of recovery from prior infectious disease , and therefore the\n person no longer represents a danger to public health.\n\n
\nThis term is for the self-declaration of illness is a document that proves that \nthe user is in a situation of illness, declared by themselves, under commitment \nof honor. Self-declaration of illness can be requested by any worker aged 16 or\n over and justifies a maximum of 3 consecutive days of absence due to illness.\n\n
\nThis term is to test for the presence of a mutation within all coding regions of\n the following genes: H3-3A, H3-3B, H3C2, H3C3 and HIST2H3C. This test does not\n differenctiate between somatic and germline alterations.\n\n
\nAdult-type diffuse gliomas are now assigned to three different tumor types: Astr\nocytoma, IDH-mutant; Oligodendroglioma, IDH-mutant and 1p/19q-codeleted; Gliobla\nstoma, IDH-wildtype. IDH-mutant diffuse astrocytic tumors are considered a singl\ne entity graded as CNS WHO grade 2, 3, or 4 depending on different histological \nand molecular features. [PMC9763975]\n\n
\nThis term is for the evaluation of microsatellite instability and mutation withi\nn all coding regions and exon/intron boundaries of 39 genes for bladder and pros\ntate cancer.\n\n
\nThis term is for the evaluation of microsatellite instability and mutation withi\nn all coding regions and exon/intron boundaries of 49 genes for gynecological ca\nncer.\n\n
\nThis term is for the evaluation of microsatellite instability and mutation withi\nn all coding regions and exon/intron boundaries of 30 genes for renal cell carci\nnoma.\n\n
\nThis term is for the evaluation of microsatellite instability and mutation withi\nn all coding regions and exon/intron boundaries of 14 genes for ovarian, fallopi\nan tube and peritoneal carcinoma\n\n
\nThis term is for the evaluation for the presence of a mutation in all coding reg\nions and exon/intron boundaries of the NTRK1, NTRK2, NTRK3 genes.\n\n
\nThis term is for the evaluation for the presence of a mutation in all coding reg\nions and exon/intron boundaries of the POLE gene.\n\n
\nThis term is for the evaluation for the presence of a mutation in all coding reg\nions and exon/intron boundaries of the SDHA, SDHB, SDHC, SDHD genes.\n\n
\nThis term is to identify the level of risk for patients being considered for a \nsentinel lymph node biopsy procedure (SLNB)\n\n
\nThis term is to test for Protonitazene which is a new, potent synthetic opioid \nbearing structural resemblance to etonitazene, a synthetic opioid that is nation\nally and internationally controlled.\n\n
\nThis term is to test for Isotonitazene (aka nitazene or "ISO") is a particular s\nynthetic opioid as dangerous and deadly as fentany. Isotonitazene was involved i\nn a substantial minority of synthetic opioid overdose.\n\n
\nUsed to order methane breath test\n\n
\nThis term is for an FDA-cleared autonomous artificial intelligence software that\n analyzes retinal fundus images to detect the presence or absence of more than m\nild diabetic retinopathy.\n\n
\nThe c.1236G>A variant of DPYD gene is part of the HapB3 haplotype, which also in\ncludes other variants such as c.1129-5923C>G. The c.1236G>A variant is consider\ned a "tagging single nucleotide polymorphism (SNP)" that can identify the HapB3 \nhaplotype. Patients who are heterozygous or homozygous for HapB3 variant are de\nficient in the DPYD enzyme, leading to increased risk toxicity from fluoropyrimi\ndine chemotherapy drugs.\n\n
\nThis test is to detect the minimal residual disease (MRD) or the small number \nof Multiple myeloma cancer cells that may remain in a patient's body after treat\nment and are not detectable using conventional diagnostic methods.\n\n
\nThis term is to capture Inadequate sleep patterns and insomnia are increasingly \nprevalent sleep disorders, often intertwined in a complex relationship that affe\ncts overall well-being.\n\n
\nThis term is for the rankings of neighborhoods by socioeconomic disadvantage in \na region of interest (e.g., at the state or national level)\n\n
\nThis term is for the rankings of neighborhoods by socioeconomic disadvantage in \na region of interest (e.g., at the state or national level)\n\n
\nThis term measures how high risk of neighborhoods impacts of disasters, includin\ng COVID-19.\n\n
\nThis term estimates the annual and monthly ground-level fine particulate matter \n(PM2.5). Based on global and regional PM2.5 concentrations using information fro\nm satellite-, simulation- and monitor-based sources.\n\n
\nThis term is for census reporting the shortage designation for which identifies \na census tract experiencing a shortage of health care services. Under the establ\nished criteria, an area with an IMU of 62.0 or below qualifies for designation a\ns an MUA. An area can receive an IMU score between 0-100.\n\n
\nThis term reports the MUA scores which depends on the Index of Medical Underserv\nice (IMU) calculated for the county. Under the established criteria, an area wit\nh an IMU of 62.0 or below qualifies for designation as an MUA. An area can recei\nve an IMU score between 0-100.\n\n
\nThis term reports income inequality, which summarizes the dispersion of income a\ncross the entire income distribution. The Gini coefficient ranges from 0, indica\nting perfect equality (where everyone receives an equal share), to 1, perfect in\nequality (where only one recipient or group of recipients receives all the incom\ne).\n\n
\nThis assay is a quantitative determination of insulin extracted from dried blood\n spots through chemiluminescent immunoassay testing. PMID[ 23056434]\n\n
\nThis term represents a digital signature document containing authenticity inform\nation for an another document to verify document integrity, authenticity, and no\nn-repudiation. Stored separately from the attested document, it serves as a 'Sig\nnature Page' that can be used to validate the original document's content withou\nt altering it.\n\n
\nBody mass index or BMI is a statistical index using a person's weight and height\n to provide an estimate of body fat in males and females of any age. Data to be \ninquired in the context of nutrition catalog.\n\n
\nScreentime (ST) refers to the total time spent on viewing screens including tele\nvision, smartphones, computer, and tablets.\n\n
\nThis term represents a test for detecting and quantifying the DNA of multiple Ca\nndida species (Candida albicans, tropicalis, dubliniensis, famata, guilliermondi\ni, and kefyr) using probe amplification. The results are reported as a threshold\n number, indicating the presence and quantity of the Candida DNA in the sample. \nThis method is particularly useful for diagnosing infections caused by these Can\ndida species in immunocompromised patients and hospital settings, as referenced \nin [PMID: 25183855].\n\n
\nThis term represents a test for detecting and quantifying the DNA of multiple Ca\nndida species (Candida glabrata, krusei, parapsilosis, and lusitaniae) using pro\nbe amplification. The results are reported as a threshold number, indicating the\n presence and quantity of the Candida DNA in the sample. This method is particul\narly useful for diagnosing infections caused by these Candida species in clinica\nl settings, as referenced in [PMID: 25183855].\n\n